Oric Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

ORIC Pharmaceuticals

14/03/2024 12:00

* Oric Pharmaceuticals Inc  ORIC.OQ  reported a quarterly
adjusted
loss of 49 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -52 cents.  The mean expectation of
nine analysts for the quarter was for a loss of 49 cents per
share. Wall Street expected results to range from -55 cents
to -44 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Oric Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 49 cents​.
    * The company reported a quarterly loss of $28.33 million.
    * Oric Pharmaceuticals Inc shares had risen by 65.5% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Oric
Pharmaceuticals Inc is $18.00 

This summary was machine generated from LSEG data March 14 at
11:59 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.49          -0.49          Met
 Sep. 30 2023      -0.46          -0.44          Beat
 Jun. 30 2023      -0.57          -0.50          Beat
 Mar. 31 2023      -0.54          -0.53          Beat